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Objective To determine the optimum duration of oral
anticoagulant therapy after an episode of deep vein
thrombosis or pulmonary embolism, or both.
DesignMulticentre, prospective, randomised study with
follow-up for one year.
Setting 46 hospitals in United Kingdom.
ParticipantsPatients aged ≥18with deep vein thrombosis
or pulmonary embolism, or both.
Interventions Three (n=369) or six months (n=380) of
anticoagulation with heparin for five days accompanied
and followed by warfarin, with a target international
normalised ratio of 2.0-3.5.
Main outcome measures Death from deep vein
thrombosis or pulmonary embolism; failure to resolve,
extension, recurrence of during treatment; recurrence
after treatment; and major haemorrhage during
treatment.
Results In the patients allocated to three months’
treatment two died from deep vein thrombosis or
pulmonary embolism during or after treatment, compared
with three in the six month group. During treatment deep
vein thrombosis or pulmonary embolism failed to resolve,
extended, or recurred in six patients in the three month
group without fatal consequences, compared with 10 in
the six month group. After treatment there were 23 non-
fatal recurrences in the three month group and 16 in the
six month group. Fatal and non-fatal deep vein
thrombosis or pulmonary embolism during treatment,
and after treatment thus occurred in 31(8%) of those who
had received three months’ anticoagulation compared
with 29 (8%) of those who had received six months’
(P=0.80, 95% confidence interval for difference −3.1% to
4.7%). There were no fatal haemorrhages during
treatment but there were eight major haemorrhages in
those treated for six months and none in those treated for
threemonths (P=0.008,−3.5% to −0.7%). Thus 31 (8%) of
the patients receiving three months’ anticoagulation
experienced adverse outcomes as a result of deep vein
thrombosis or pulmonary embolism or its treatment
compared with 35 (9%) of those receiving six months’
(P=0.79, −4.9% to 3.2%).Copyright 2007 BMJ Publishing GConclusion For patients in the UK with deep vein
thrombosis or pulmonary embolism and no known risk
factors for recurrence, there seems to be little, if any,
advantage in increasing the duration of anticoagulation
from three to six months. Any possible advantage would
be small and would need to be judged against the
increased risk of haemorrhage associated with the longer
duration of treatment with warfarin.
Trial registration Clinical Trials NCT00365950.INTRODUCTION
In 1960 Barritt and Jordan established that anti-
coagulation reduced the risk of death and of recurrent
embolism in patients with pulmonary embolism,1 a
conclusion subsequently supported by retrospective
studies from Oxford2 and the United States.3 Treat-
ment regimens now consist of heparin for four to five
days,4-6 with anticoagulation maintained thereafter by
warfarin. In the 1970s and 1980s three relatively small
randomised trials suggested that therewas nobenefit in
anticoagulation for more than three to six weeks7-9 but
practice in United Kingdom and abroad continued to
vary widely.10 In 1992, the British Thoracic Society
published the results of a largemulticentre prospective
study, which indicated that because the outcome with
three months’ anticoagulation was significantly better
than with one month, three months’ anticoagulation
should be given to patients with pulmonary venous
thromboembolism (first episode or no episode for the
previous three years).11 12 This recommendation has
not been universally accepted, with authoritative
sources in the UK, North America, and Europe conti-
nuing to recommend six months or more.13-16 To
obtain further evidence, the British Thoracic Society
designed and conducted another multicentre study to
compare the outcomes of two durations of anti-
coagulation, three and six months, with warfarin after
initial heparin therapy.
For those centres not already routinely using low
molecular weight heparin, an expanded design was
used to compare low molecular weight heparin withpage 1 of 7
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page 2 of 7unfractionated heparin in terms of outcome during
treatment outcome after the end of anticoagulation,
and duration of inpatient stay. Too few patients
(n=22) were entered into this randomisation for mean-
ingful comparions of these outcomes and so we used
their results solely in the comparisons of three months
versus six months of anticoagulation.
METHODS
Patients
Eligible patients were those aged ≥18with suspected or
proveddeep vein thrombosis or pulmonary embolism,
or both, whom the clinician intended to treat with anti-
coagulant. We encouraged confirmation of diagnosis
with ultrasound, radioisotope, venographic, angio-
graphic, or other objective tests but patients managed
without the aid of such tests were accepted for the trial.
Categories of definite, probable (high or moderate
probability), low probability, or negative were taken
from the reports of the results.
Several factors or conditions excluded patients from
entry. These were deep vein thrombosis or pulmonary
embolism deemed so severe by the clinician as to
require thrombolysis or pulmonary embolectomy;
neoplasia diagnosed or requiring treatment, or both,
within the previous three years; pregnancy; deep vein
thrombosis or pulmonary embolism in the preceding
three years; known polycythaemia, thrombocythae-
mia, antithrombin III deficiency, lupus anticoagulant,
homozygous factor V Leiden, protein C or protein S
deficiency, or other similar predisposing haematologi-
cal disorders; any condition that would result in pro-
longed or continuous immobility or confinement to
bed, such as advanced multiple sclerosis or orthopae-
dic problems of the lower limbs; previous allergy to
heparin or warfarin; requirement for long term anti-
coagulant therapy; and inability to give informed con-
sent.
Design
Patients were randomised to three or six months of
warfarin, the clinicians being asked to start warfarin
on day one of the scheduled five days of heparin. Par-
ticipating physicians used international normalised
ratios tomonitor anticoagulationwithwarfarin accord-
ing to a standardised protocol.17 The aim was to
achieve ratios between 2.0 and 3.5.
Within each centre randomisation was by permuted
blocks of eight through a series of numbered envelopes
kept at a central point in each hospital or unit. Each
envelope also contained an entry card to be posted to
the coordinator as notification of entry. On receipt of
that card the coordinator sent a form to the clinician,
confirming the allocated treatment and requesting
further details of the patient. This form also contained
a section for the clinician to notify the coordinator of
alteration of diagnosis or discontinuation of anti-
coagulation, or both: if a patient was found to fulfil
any of the criteria for exclusion, that patient wasremoved from the analysis before we had any knowl-
edge of the outcome of the study.
The individual clinicians were responsible for deci-
sions about inpatient or outpatient management. For
purposes of the trial, physicians were asked to arrange
follow-up appointments at three, six, and 12 months
from the date of entry. Brief review forms were sent
to the clinician a fortnight or so before each follow-up
date for completion and return to the coordinator. The
forms requested information on failure of resolution
(swelling of the leg(s) or pain or tenderness that did
not settle down during treatment), extension or recur-
rence of deep vein thrombosis or pulmonary embo-
lism, results of international normalised ratios, dates
of start and completion of therapy with heparin and
with warfarin, and adverse events. Clinicians were
asked to confirm suspected failure of resolution, exten-
sion, or recurrence by radiological or ultrasonic ima-
ging, or both.
Predetermined primary adverse outcomes were
death from deep vein thrombosis or pulmonary embo-
lism, failure during treatment (failure to resolve, exten-
sion, recurrence during treatment), recurrence after
the end of treatment, and major haemorrhage during
treatment. Patients experiencing any of the abovewere
grouped together under the heading of “adverse out-
come,” and we reported this as a further point of com-
parison between the groups.
We graded anticoagulation as good if the inter-
national normalised ratios were between 2.0 and 3.5
on at least two thirds of occasions, moderate if within
that range on a third but less than two thirds of occa-
sions, or poor if within that range for less than a third of
occasions, as used previously.11 For patients in the six
month group we applied these gradings separately for
the first threemonths and for the second threemonths.
Haemorrhage was defined as major if the treating
clinician deemed transfusion necessary, if the haemo-
globin concentration fell by 20 g/l, if bleeding was
intracranial or retroperitoneal, or if it was sufficiently
serious for the clinician to discontinue anticoagulation.
Each participant gave written informed consent
before entry into the trial, and clinicians used standar-
dised letters to inform the patients’ general practi-
tioners.
Statistical analysis
We calculated that we would need 2400 patients to
have 80% power to detect a difference, significant at
the 5% level, between recurrence rates of 6% and 9%.
The coordinator and the coordinating physician
checked all entry forms on receipt to ensure the
patients’ eligibility. After exclusion of ineligible
patients we analysed the results by standard statistical
methods according to the randomisation to define a
full analysis population.18
Type of anticoagulant
We offered centres a supply of a lowmolecular weight
heparin (dalteparin) to use in the trial. In centresBMJ | ONLINE FIRST | bmj.com
Randomised (n=810)
Allocated to 3 month group (n=396):
  Received allocated intervention (n=369)
  Did not receive allocated intervention (n=27):
    Not DVT/PE (n=11)
    DVT within previous 3 years (n=4)
    Known cancer (n=8)
    Polycythaemia (n=2)
    Immobility (n=1)
    Insufficient data (n=1)
Allocated to 6 month group (n=414):
  Received allocated intervention (n=380)
  Did not receive allocated intervention (n=34):
    Not DVT/PE (n=20)
    DVT within previous 3 years (n=3)
    Known cancer (n=11)
Analysed (n=369)
Deaths:
  DVT/PE (n=2)
  Other (n=12)
Followed to
1 year
(n=349)
Analysed (n=380)
Deaths:
  DVT/PE (n=3)
  Other (n=16)
Followed to
1 year
(n=357)
Lost before
1 year
(n=6)
Lost before
1 year
(n=4)
Fig 1 | Flow of patients through trial (DVT=deep vein thrombosis; PE=pulmonary embolism)
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BMJ | ONLINE FIRST | bmj.comalready using another low molecular weight heparin
we asked participating clinicians to change to dalte-
parin, but inability or unwillingness to do so did not
exclude their patients from the trial. The standard
oral anticoagulant was warfarin, but clinicians could
use an alternative coumarin if necessary.
RESULTS
From mid-September 1999 to the end of December
2002, 137 consultants from 46 hospitals (37 in Eng-
land, four in Scotland, four inWales, and one inNorth-
ern Ireland) entered 810 patients. Sixty one patients
were excluded from analysis because they did not
satisfy the entry criteria (27 in the three month group,
34 in the sixmonth group), leaving 369 patients rando-
mised to three months of treatment and 380 to treat-
ment for six months (fig 1). These two groups were
comparable over a broad range of characteristics,
though a slightly higher proportion of men and of
patients with pulmonary embolism were allocated toTable 1 | Characteristics of treatment groups at entry to trial. Figure
Three mon
Mean (SD) age (years) 59
Patients
Men 1
DVT only 2
PE with or without overt DVT 9
Objective confirmation sought 3
Confirmed as definite or probable 3
Underlying causes of DVT/PE
None evident 1
Recent surgery 4
Short term immobility 7
DVT/PE >3 years before or family history of DVT/PE, or both
Postpartum, contraceptive pill, or HRT
Travel
Other
DVT=deep vein thrombosis; PE=pulmonary embolism; HRT=hormone replacemsix months’ treatment (table 1). Diagnosis was con-
firmed as definite in 91% of those receiving three
months’ anticoagulation and 92% of those receiving
six months’ and as probable in 6% and 6%, respec-
tively, an overall frequency of definite or probable of
97%.
Among those forwhomwehad thedata, heparinwas
given for three to seven days in 74% of patients in the
three month group and 77% of those in the six month
group (table 2). The minority of patients who received
heparin for less than five days did so because the target
international normalised ratio had been achieved
early. Among those who received more than five
days’ heparin the usual reason was that the target
ratio had not been achieved, though in a few patients
an intervening weekend seemed to be the only reason.
If we allowed three weeks either side of three months
and six weeks either side of six months and considered
those in whom durations were known (322 of three
month group and 348 of six month group), 259 (80%)
of those allocated to three months’ treatment and 307
(88%) of those allocated sixmonths received treatment
with warfarin as per protocol. In those with shorter or
longer durations, variations were because of errors by
physicians or general practitioners, misunderstanding
in patients, and rescheduling of follow-up clinics.
Control ofwarfarin therapywas goodormoderate in
most patients, but at the three month follow-up 42
(13%) of 335 patients in the three month group with
sufficient data were graded as poorly controlled, as
were 37 (11%) of 340 in the six month group. Control
improved between three and six months, and among
those with sufficient data (n = 313), only 11 (4%) were
graded as poorly controlled. Two patients (both in the
six month group) could not tolerate warfarin and were
changed to alternative coumarins.
Table 3 shows themain outcomes. During treatment
four patients died from deep vein thrombosis or pul-
monary embolism (one in the three month group,
three in the six month group), and one patient in thes are numbers (percentages) unless stated otherwise
th group (n=369) Six month group (n=380) Total (n=749)
.0 (15.7) 58.5 (15.0) 58.7 (15.4)
83 (50) 215 (57) 398 (53)
71 (73) 257 (68) 528 (70)
8 (27) 123 (32) 221 (30)
65 (99) 378 (99) 743 (99)
56 (96) 370 (97) 726 (97)
55 (42) 179 (47) 334 (45)
4 (12) 42 (11) 86 (11)
9 (21) 74 (19) 153 (20)
9 (2) 12 (3) 21 (3)
15 (4) 17 (4) 32 (4)
32 (9) 32 (8) 64 (9)
35 (9) 24 (6) 59 (8)
ent therapy.
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Table 2 | Details of treatment in patientswith deep vein
thrombosis or pulmonary embolism according to length of
anticoagulation
Three
month
group
(n=369)
Six month
group (n=380)
Type of heparin:
Dalteparin 235 238
Tinzaparin 117 126
Other (including unfractionated
heparin)
17 15
Not known 0 1
Duration of heparin (days):
1-2 25 25
3-7 267 285
>7 67 61
Not known 10 9
Duration of warfarin (weeks):
<9 11 7
9-15 259 17
>15-<18 27 5
18-30 25 307
>30 0 12
Not known 47 32
Warfarin control:
At 0-3 months:
Good 201 208
Moderate 92 95
Poor 42 37
Insufficient data 34 40
At 3-6 months:
Good — 227
Moderate — 75
Poor — 11
Insufficient data — 67
Table 3 | Outcomeat one year in pa
according to length of anticoagul
Deaths from PE during or after treatme
Deaths from haemorrhage during treat
Deaths from known other causes durin
Outcome at one year unknown
Non-fatal extensions, failures of resolu
DVT/PE
Major non-fatal haemorrhages during t
Adverse outcome as a result of DVT/PE
PE=pulmonary embolism; DVT=deep ve
*Includes one patient who died from h
received further anticoagulation.
†Two patients had non-fatal extension,
haemorrhages.
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Recurrence in three month group
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Fig 2 | Cumulative incidence of failure of treatment or
recurrenceof deepvein thrombosis or pulmonary embolism in
the treatment groups
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page 4 of 7three month group died from deep vein thrombosis or
pulmonary embolism one month after completing
treatment, an overall mortality of 0.7%.
Twelve patients in the three month group and 16 in
the six month group died from causes other than deeptientswith deep vein thrombosis or pulmonary embolism
ation
Three month group
(n=369)
Six month group
(n=380)
nt 2 (0.5%) 3 (0.8%)
ment 0 0
g or after treatment 12 16*
6 4
tion, or recurrences of 29 (8%) 26 (7%)*†
reatment 0 8 (2%)†
or its treatment 31 (8%) 35 (9%)
in thrombosis.
aemorrhage after end of treatment, having had recurrence of DVT/PE and
failure of resolution, or recurrence of DVT/PE as well major non-fatalvein thrombosis or pulmonary embolism during and
after treatment, one of whom (in the six month group)
died at home from an unspecified cerebrovascular
event during treatment. For 10 patients (six in the
three month group and four in the six month group)
we had no information on whether they were alive or
had died by the end of their year in the trial. None of
these 10 patients had experienced any adverse out-
come of deep vein thrombosis or pulmonary embo-
lism or its treatment up to the time they were last seen
by their doctors.
In six patients in the three month group and 10
patients in the six month group deep vein thrombosis
or pulmonary embolism failed to resolve, extended, or
recurred during treatment without fatal consequences.
After the end of treatment there were 23 non-fatal
recurrences in the three month group and 16 in the
six month group. Therefore there were 29 (24, 83%)
were objectively confirmed) non-fatal failures to
resolve, recurrences, or extensions during treatment
plus recurrences after treatment in the three month
group and 26 (20, 77%) were objectively confirmed)
in the six month group (table 3). Fatal and non-fatal
failures during treatment plus recurrences after treat-
ment thus occurred in 31(8.4%) patients in the three
month group and 29 (7.6%) in the six month group
(P=0.80, 95% confidence interval for difference
−3.1% to 4.7%) (fig 2).
During treatment no one in the three month group
experienced major non-fatal haemorrhages, though
eight (2%) in the six month group did so (one in the
second month, two in the third month, and five in the
fourth month), one of whom also experienced failure
during treatment and one experienced relapse after
treatment (P=0.008, 95% confidence interval for differ-
ence −3.5% to −0.7%). None of these occurred when
patients were receiving heparin.
Thus all adverse outcomes (deaths from deep vein
thrombosis or pulmonary embolism, major haemor-
rhages during treatment, failures during treatment,
and recurrences after treatment) as a result of deep
vein thrombosis or pulmonary embolism or itsBMJ | ONLINE FIRST | bmj.com
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Treatment for three months
Treatment for six months
Fig 3 | Cumulative incidence of adverse outcomes in the two
treatment groups
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BMJ | ONLINE FIRST | bmj.comtreatment occurred in 31 (8%) patients allocated to
threemonths’ treatment and 35 (9%) patients allocated
to six months’ treatment (fig 3) (P=0.79, −4.9% to
3.2%).
In relation to outcome, there was no interaction
between the duration of treatment and the original
diagnosis (logistic regression P=0.44). Overall, 221
(30%) of the 749 patients presented with pulmonary
embolism (with or without evidence of deep vein
thrombosis) and 22 (10%) of them experienced fatal
and non-fatal failures of resolution or recurrences, or
both, whereas among the 528 patients who presented
with deep vein thrombosis alone there were 38 (7%)
fatal and non-fatal failures of resolution or recurrences,
or both, during and after treatment (P=0.26, −1.8% to
7.3%).
The proportions of failures of resolution, extension,
or recurrence of deep vein thrombosis or pulmonary
embolism were similar in those who had received dal-
teparin (35/473; 7%), tinzaparin (22/243; 9%), and
enoxaparin (3/22; 14%) (χ2=1.5, df=2, P=0.47).
DISCUSSION
Outcomes and relevance to practice
In this trial 8%of patients with deep vein thrombosis or
pulmonary embolism experienced fatal and non-fatal
failures of resolution, extension, or recurrence during
and after three months of anticoagulation. The results
were similar in those patients who had received six
months’ anticoagulation but in this group 2% experi-
enced major haemorrhages during treatment, whereas
none of those treated for three months did. As we con-
ducted the study across a wide range of acute hospitals
in the UK, our results are likely to be representative of
those that pertain in routine practice.
Comparison with previous studies
Previous randomised trials that had included at least
100 patients with deep vein thrombosis or pulmonary
embolism reported failures during treatment and
recurrences after treatment for six months in 9-17% of
patients.7 8 17 In 1992 the first British Thoracic Society
study, conducted in a similar setting, reported that 8%
of patients who had received three months’ anti-
coagulation experienced failure during treatment orrecurrence after end of treatment, or both.11 More
patients in our study underwent confirmatory investi-
gations at initial presentation than in the previous study
(99% v 83%), with definite confirmation of diagnosis in
97% v 71%.We were able to establish objective confir-
mation of non-fatal failures during treatment or
relapses after treatment in 80% compared with 42%
in the earlier study.11 Pinede et al directly compared
three and six months’ treatment and reported an 8%
rate of failure during treatment or recurrence after the
end of treatment for both durations of anticoagulation
.19 Schulman et al randomised patients to six weeks’ or
sixmonths’ treatment and reported recurrence rates of
18% at two years with six weeks’ treatment and 9%
with six months’ treatment.14 When the follow-up in
that study was extended to six years, the recurrence
rates rose to 28% in the six week group and 21% in
six month group, leading the authors to conclude that
there was a cumulative risk of recurrence of 4-5% a
year after the index event, independent of the initial
duration of anticoagulation.20 After 10 years of fol-
low-up there was no significant difference between
the recurrence rates (31% and 27%).21 In 2001 and
2003 Agnelli and colleagues published two studies in
which they had followed patients for two years: recur-
rence rates in those receiving three months’ treatment
varied between 12%and 16%, comparedwith 12%and
17% in those receiving 12 months’ treatment. The
authors concluded that for patients with deep vein
thrombosis or pulmonary embolism prolonging anti-
coagulant therapy beyond three months simply
delayed recurrence until anticoagulation was
stopped.22 23 Kearon et al compared three months’
treatment with extended therapy and concluded that
patients with a first episode of idiopathic deep vein
thrombosis or pulmonary embolism should be treated
for longer than three months.24 The design of their
study did not allow them to say how much longer and
in this relatively small study a high proportion (17 of
83) of those assigned to receive placebo after three
months had recurrences (27% per patient per year)
compared with only one of 79 assigned to receive war-
farin (1.3% per patient per year, P<0.001). In addition
the rate of major bleeding in the extended treatment
group was 3.8% a year compared with 0% a year in
the three month group.24 In our study, at one year the
numbers of patients with failure of resolution during
treatment and recurrences after the end of anti-
coagulation were only marginally and non-signifi-
cantly greater among those who had received three
months’ treatment rather than six months’ treatment
(31/369 v 29/380).
One year mortality from deep vein thrombosis or
pulmonary embolism in previous clinical trials ranged
from 0% to 2.2%,89 14 19 22-24 the previous study in 1992
reporting a rate of 1%,11 whereas the 1996 and 2000
cohort studies each noted mortality of 0.5%.25 26 The
0.7% rate in the current study is well within this
range. In terms of deaths from deep vein thrombosis
or pulmonary embolism there was no significantpage 5 of 7
WHAT IS ALREADY KNOWN ON THIS TOPIC
In patients with deep vein thrombosis or pulmonary embolism, or both, anticoagulation with
heparin and warfarin reduces mortality and morbidity
Treatment for four to six weeks is usually enough for patients in whom the cause is transient
In other instances treatment for three months or more is necessary
WHAT THIS STUDY ADDS
For patients with deep vein thrombosis or pulmonary embolism in whom there are no
persistent risk factors three months’ anticoagulation is as effective as six months’ treatment
and is associated with a lower risk of major bleeding
RESEARCH
page 6 of 7difference between the two groups (2/369 in the three
month group v 3/380 in the six month group).
Major haemorrhages
A meta-analysis published in 2005 suggested that the
risk (weighted incidence rate) of major bleeding was
similar for patients receiving long term anticoagulation
and those on short term regimens.27 Our results
showed an overall rate of 1% in the trial as a whole,
though the longer regimenof anticoagulationwas asso-
ciated with a 2% risk of major bleeding over the six
month period of treatment. In our study there was
only one death that might possibly have been caused
by intracranial haemorrhage, a patient who died at
home during the fifth month from an unspecified
cerebrovascular event while receiving treatment in
the six month group. In the clinical trials between
1990 and 2005, deaths from major haemorrhage were
reported in 0.1% to 0.4% of patients receiving three
months’ treatment compared with 0.1% in those
receiving sixmonths’ treatment.11 14 19 22-24 In the cohort
studies of 1996, 2000, and 2005 the death rate from
major haemorrhage was 0.5% in those receiving three
months’ anticoagulation.25-28
Factors affecting sample size
Though we achieved a larger sample size than many
other trials, it was disappointing relative to our planned
sample. The start of the trial was delayed initially by
difficulties with obtaining finance. Then, after we
obtained permission to do the trial from a multicentre
research ethics committee, further difficulties and
delays were caused by local committees in several cen-
tres. As a result some physicians withdrew from the
trial. Furthermore, by the time the intake began many
centres that had been willing to participate in the com-
parison of unfractionated heparin versus low molecu-
lar weight heparin had already switched to the routine
use of low molecular weight heparin and physicians at
those centres were unwilling to randomise patients
between the two. All this occurred at a time of steep
increase in workload generated by a rise in numbers
of emergency medical admissions. These factors com-
bined to reduce the number of patients recruited. The
result of the reduction in sample size has been to
increase the standard error of the differences for the
primary outcome variables between the two periods
of anticoagulation to 2% compared with an expected
standard error with the original design of just over 1%.The observed differences for the primary outcome
variables, however, are small, excluding substantial
differences in favour of either length of treatment.
Conclusions
For patients with deep vein thrombosis or pulmonary
embolism occurring in circumstances other than the
presence of major thrombophilias or other persisting
risk factors, our results do not affect the advice pre-
viously given in the British Thoracic Society
guidelines.29 In terms of efficacy, three months’ anti-
coagulationwas associatedwithmuch the same benefit
as six months’ anticoagulant treatment but the shorter
regimen seems to be associated with a lower incidence
of haemorrhage during treatment. Further large, well
designed trials are needed to establish the optimum
duration of anticoagulation in various subgroups,
including more studies of the place of d-dimer testing
in determining duration.30
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